Growth Plus Reports Logo.jpg
Anti-Obesity Drugs Market Set to Register a CAGR of 16.10% and Reach USD 7.97 Billion by 2031 – Growth Plus Reports
April 10, 2023 09:00 ET | Growth Plus Reports
Newark, New Castle, USA, April 10, 2023 (GLOBE NEWSWIRE) -- According to a recent Growth Plus Reports assessment, the anti-obesity drugs market is estimated to reach US$ 7.97 billion by 2031, with a...
Ellen AB har erhålli
Ellen AB har erhållit en första uppfyllnadsorder för implementering av de probiotiska tampongerna i de fysiska butikerna på Norges största apotekskedja, Apotek 1
February 23, 2021 10:13 ET | Ellen AB
Ellen AB har tidigare kommunicerat att de utvidgar sin distribution och affär i Norge via Apotek 1, Norges största apotekskedja. Nu har den första uppfyllnadsordern kommit för återlansering och...
ReportLinker logo.jpg
Bone and Joint Health Supplements market worldwide is projected to grow by US$5.3 Billion
May 22, 2020 22:13 ET | ReportLinker
New York, May 22, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Bone and Joint Health Supplements Industry" -...
22157.jpg
Outlook on the World Market for Anti-Obesity Drugs 2019-2024
June 21, 2019 05:15 ET | Research and Markets
Dublin, June 21, 2019 (GLOBE NEWSWIRE) -- The "Anti-Obesity Drugs: Global Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering. This...
Navamedic ASA: Tom Rönnlund to step down as CEO
October 01, 2018 02:31 ET | Navamedic
Oslo, Oct 1, 2018 - Navamedic ASA (OSE: NAVA) today announces that Tom Rönnlund has tendered his resignation as CEO of Navamedic ASA and will leave the company at the end of 2018 to take up a position...
Navamedic ASA: Resultater for Q2 2018
August 24, 2018 01:58 ET | Navamedic
  Oslo, 24. august 2018 - Navamedic ASA (OSE: NAVA) rapporterte driftsinntekter på NOK 45,2 millioner i andre kvartal 2018, ned fra NOK 89,7 millioner i samme periode i 2017, etter det planlagte...
Navamedic ASA: Q2 2018 results
August 24, 2018 01:58 ET | Navamedic
  Oslo, August 24, 2018 - Navamedic ASA (OSE: NAVA) reported revenues of NOK 45.2 million in the second quarter of 2018, down from NOK 89.7 million in the same period in 2017, following the...
Navamedic ASA: Resultater for Q2 2018
August 24, 2018 01:25 ET | Navamedic
Oslo, 24. august 2018 - Navamedic ASA (OSE: NAVA) rapporterte driftsinntekter på NOK 45,2 millioner i andre kvartal 2018, ned fra NOK 89,7 millioner i samme periode i 2017, etter det planlagte utløpet...
Navamedic ASA: Q2 2018 results
August 24, 2018 01:25 ET | Navamedic
Oslo, August 24, 2018 - Navamedic ASA (OSE: NAVA) reported revenues of NOK 45.2 million in the second quarter of 2018, down from NOK 89.7 million in the same period in 2017, following the planned...
Navamedic ASA: Renews multiple key distribution agreements
August 21, 2018 02:01 ET | Navamedic
  Oslo, August 21, 2018 - Navamedic ASA (OSE: NAVA) today announced it has renewed three partnership agreements with Vitaflo International Limited, Allerderm Laboratories and Qiagen GmbH for...